Byron Tart
This article was originally published in The Gray Sheet
Executive Summary
CDRH promotion and policy staff director retires May 31. Tart has held the position since 1993 and has been at the device center since 1990. Deborah Wolf is named acting director
You may also be interested in...
CDRH promotion and policy staff
Regulatory Counsel Terri Garvin becomes acting director of FDA device center's promotion and advertising policy staff within the Office of Compliance Oct. 1. Regulatory Counsel Deborah Wolf has held the position since Byron Tart's retirement May 31 (1"The Gray Sheet" June 4, 2001, In Brief)
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.